معرفی
Guy Bormans is a Full Professor at KU Leuven's Faculty of Pharmaceutical Sciences, where he leads the Radiopharmaceutical Research unit. He also heads the Subdivision of Radiopharmacy, Miracle Radiopharmacy Subdivision, and Miracle-GB Sub-Division. He is a member of the Division Center for Drug Delivery and Analysis, Division of Molecular Imaging Research and Clinic Leuven, and LBI - KU Leuven Brain Institute. Additionally, he serves as Program Director of the POC Interuniversity Steering Group at Manama Hospital Pharmacy.
His research focuses on radiopharmaceutical development, particularly PET tracers targeting heat shock protein 90 (Hsp90) and CXCR4 receptors for applications in oncology and neurodegenerative diseases. Key areas include:
- Design of radiotracers for molecular imaging and radionuclide therapy
- Translational studies bridging preclinical models and clinical diagnostics
- Quantitative PET/CT methodology for neuroendocrine tumors and brain disorders
Analysis of his 15 most recent publications (2024–2025) reveals a dominant focus on Hsp90 and CXCR4-targeted PET imaging, with innovations in radioligand design (e.g., nanobodies, deuterated compounds), kinetic modeling, and clinical validation for cancer/neurodegenerative diseases. Recurring themes include theranostic applications and overcoming biological barriers (e.g., blood-brain penetration).
He currently supervises doctoral students including V. Narykina (Hsp90 cancer imaging) and R. Cools (Hsp90 radiotracer development). Major funded projects he leads or co-leads include:
- Development of TRNT radiopharmaceuticals targeting Hsp90 (2024–2028)
- Peptide-based CXCR4 targeting for PET/radionuclide therapy (2021–2024)
- IMAGINATION: Biomarkers for diagnosis/therapeutics (2022–2025)
- Research on radioactive cores at ISOLDE-CERN/SPIRAL2-GANIL (2023–2026)
He directs laboratories specializing in radiopharmacy, molecular imaging, and radionuclide therapy within KU Leuven's Radiopharmaceutical Research division.
